Search Results

Arbor Biosciences announced a partnership with Biosearch Technologies, the complete genomics portfolio of LGC Group.

OliX Pharmaceuticals, Inc. announced that the Company signed an exclusive contract with LGC Biosearch Technologies Inc., a contract development and manufacturing organization and part of the global life sciences tools company headquartered in London, to scale production of OliX’s OLX301D therapeutic candidate.

LGC, Biosearch Technologies proudly introduces RapiDxFire™ Thermostable RT, a truly thermostable reverse transcriptase designed specifically to meet the needs of diagnostic kit developers.

LGC, Biosearch Technologies today announces the release of a new set of ValuPanel™ Reagents to help the efforts of public health laboratories to detect SARS-CoV-2, influenza A, and influenza B.

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), announced that the companies signed an exclusive contract to scale production of OliX’s OLX104C, an investigational RNAi therapeutic in development for the treatment of androgenic alopecia.

ANN ARBOR, Mich. , Feb. 24, 2020 /PRNewswire/ -- Swift Biosciences, Inc., a leader in commercialization of DNA and RNA library preparation kits for Next-Generation Sequencing (NGS), today announced a partnership agreement with LGC, Biosearch Technologies, a global leader in specialty genomic analysis tools to leverage Swift’s targeted sequencing technology into LGC Biosearch T

Alliance Pharma, a U.S. leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, closed on the purchase of Drug Development Solutions, a U.K.-based bioanalytical and material science testing contract research organization, from LGC.

After revoking Sarepta’s award in July and awarding one to Krystal last month, the FDA’s platform technology designation program appears to be back on track. These six biotechs could be on the regulator’s radar.